NCT05560971View on ClinicalTrials.gov

Monounsaturated Fatty Acid Supplementation for Overweight and Obese Individuals With Prediabetes

NAActive, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
PreDiabetesInsulin ResistanceOverweightObesity
Interventions
DIETARY_SUPPLEMENT

Palmitoleic acid

Participants will be randomized to either POA or placebo and will be asked to take 2 capsules of the POA or placebo twice a day for 8 weeks.

OTHER

Placebo

Medium chain fatty acids in triglyceride form in capsules with the same shape, color, size and odor of POA capsules

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

Tersus Life Sciences LLC

INDUSTRY

lead

Brigham and Women's Hospital

OTHER